| Literature DB >> 35681681 |
Mitsuru Okuno1, Tsuyoshi Mukai1,2, Keisuke Iwata1, Naoki Watanabe3, Takuji Tanaka3, Taisei Iwasa1, Kota Shimojo1, Yosuke Ohashi1, Akihiro Takagi1, Yuki Ito1, Ryuichi Tezuka1, Shota Iwata1, Yuhei Iwasa1, Takahiro Kochi1, Tomio Ogiso1, Hideki Hayashi1, Akihiko Sugiyama1, Youichi Nishigaki1, Eiichi Tomita1.
Abstract
The specimen collection and subsequent pathological diagnosis of malignant biliary stricture (MBS) are difficult. This study aimed to determine whether the cell block (CB) method using overnight-stored bile is useful in the diagnosis of MBS. This trial was a single-arm prospective study involving a total of 59 patients with suspected MBS. The primary endpoint was cancer detectability and accuracy using the CB method, and a comparison with the detectability and accuracy achieved with bile cytology was made. The immunohistochemical sensitivity for maspin and p53 was also investigated in the CB and surgical specimens. We were able to collect bile from all 59 patients, and 45 of these patients were clinically diagnosed with MBS. The cancer detectability using the CB method (62.2%) was significantly higher than that using cytology (37.8%) (p = 0.0344). When CB was combined with biopsy, the rates of cancer detectability (75.6%) and accuracy (81.4%) increased. In eight patients who received surgical therapy, maspin- and p53-immunohistochemistry was applied to the surgical and CB specimens, and cancer cells in both specimens showed positive cytoplasmic and nuclear staining for maspin and nuclear staining for p53. The CB method is, thus, useful for detecting malignancy (UMIN000034707).Entities:
Keywords: bile cytology; bile duct biopsy; cell block; endoscopic retrograde cholangiography; immunohistochemistry; malignant biliary strictures
Year: 2022 PMID: 35681681 PMCID: PMC9179241 DOI: 10.3390/cancers14112701
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Study patient flow.
Figure 2The cell block method was performed using overnight-stored bile. (A) Suspicious malignant biliary stricture (MBS) was detected in the middle bile duct (arrow). Endoscopic nasobiliary drainage (ENBD) tube was placed in the occluded bile duct. (B) Bile from the ENBD tube was stored overnight after ENBD tube placement. (C) The stored bile was processed by centrifugation for 10 min. (D) Only the precipitate (arrowhead) was collected and fixed in 10% neutral buffered formalin. (E) The precipitate was then embedded in paraffin wax. (F) The malignant specimen could be detected by hematoxylin and eosin staining of the section.
Patients’ baseline characteristics.
| Sex, female/Male | 23 (38.3%)/37 (61.7%) |
| Age (years), median (range) | 76 (49–98) |
| Endoscopic sphincterotomy | 46 (76.7%) |
| Diameter of ENBD tube 5 Fr:6 Fr (number) | 32:28 |
| Eastern cooperative oncology group performance status (ECOG-PS), | |
| 0 | 28 |
| 1 | 16 |
| 2 | 13 |
| 3 | 3 |
| Alanine aminotransferase (AST), median (range), IU/L | 89 (13–540) |
| Aspartate aminotransferase (ALT), median (range), IU/L | 119 (9–1246) |
| Total bilirubin level, median (range), mg/dL | 1.5 (0.3–34.2) |
| White blood count, median (range)/µL | 6490 (2890–20750) |
| Neutrophils, median (range)/µL | 4150 (1030–19090) |
| Hemoglobin, median (range), g/dL | 12.0 (8.7–15.8) |
| Location of stricture in the bile duct | |
| Intrahepatic | 6 (10.0%) |
| Portal | 16 (26.7%) |
| Superior | 17 (28.3%) |
| Inferior | 21 (35.0%) |
| Type of malignancy, | |
| Extrahepatic cholangiocarcinoma | 26 (43.4%) |
| Gallbladder cancer | 7 (11.7%) |
| Ampullary cancer | 5 (8.4%) |
| Pancreatic head cancer | 4 (6.6%) |
| Intrahepatic cholangiocarcinoma | 2 (3.3%) |
| Hepatocellular carcinoma | 1 (1.7%) |
| Benign, | |
| Primary sclerosing cholangitis | 4 (6.6%) |
| IgG4-related sclerosing cholangitis | 4 (6.6%) |
| Bile duct hamartoma | 1 (1.7%) |
| Liver cirrhosis | 1 (1.7%) |
| Acalculous cholecystitis | 1 (1.7%) |
| Other inflammatory non-malignant stenosis | 3 (5.0%) |
| Withdrawal case due to patient’s will | 1 (1.7%) |
Figure 3Outline of the process used to reach the final diagnosis. BSC, best supportive care; EC, extrahepatic cholangiocarcinoma; AC, ampullary cancer; GC, gallbladder cancer; PC, pancreatic cancer; IC, intrahepatic cholangiocarcinoma; HCC, hepatic cell carcinoma; IgG4-SC, IgG4-related sclerosing cholangitis; PSC, primary sclerosing cholangitis; BDH, bile duct hamartoma; LC, liver cirrhosis; and AcC, acalculous cholecystitis.
Comparison of cancer detectability using the cell block (CB) method and bile cytology.
| Overall ( | CB Method, | Bile Cytology, | |
|---|---|---|---|
| Malignant ( | 28 (62.2%) | 17 (37.8%) | 0.0344 |
| Extrahepatic cholangiocarcinoma ( | 15 (57.7%) | 12 (46.2%) | 0.58 |
| Gallbladder cancer ( | 7 (100%) | 2 (28.6%) | 0.0210 |
| Ampullary cancer ( | 3 (60.0%) | 1 (20.0%) | 0.52 |
| Pancreatic head cancer ( | 1 (25.0%) | 1 (25.0%) | 1.0 |
| Intrahepatic cholangiocarcinoma ( | 2 (100%) | 1 (50.0%) | 1.0 |
| Hepatic cell carcinoma ( | 0 (0%) | 0 (0%) | 1.0 |
| Benign ( | 14 (100%) | 14 (100%) | 1.0 |
Diagnostic efficacy of the cell block (CB) method, bile cytology, and biopsy.
| CB Method | First Bile Cytology | Multiple Bile Cytology | Biopsy | |
|---|---|---|---|---|
| Sensitivity | 62.2% (28/45) | 37.8% (17/45) * | 60.0% (27/45) | 65.8% (25/38) |
| Specificity | 100% (14/14) | 100% (14/14) | 100% (14/14) | 100% (9/9) |
| PPV | 100% (28/28) | 100% (17/17) | 100% (27/27) | 100% (25/25) |
| NPV | 45.2% (14/31) | 33.3% (14/42) | 43.8% (14/32) | 40.9% (9/22) |
| Accuracy | 71.2% (42/59) | 52.5% (31/59) † | 69.5% (41/59) | 72.3% (34/47) |
* p < 0.05, compared with the CB method (Fisher’s test). † p = 0.0575, compared with the CB method (Fisher’s test).
Comparison of diagnosis using the cell block (CB) method and biopsy in malignant disease.
| CB Method | ||
|---|---|---|
| Malignant ( | False Negative ( | |
| Biopsy | ||
| Malignant ( | 19 | 6 |
| False negative ( | 7 | 6 |
| Unperformed case ( | 2 | 5 |
Figure 4The comparison of malignant cell count on the cell block (CB) and biopsy specimens. (A) Degenerated cells (arrowhead) and cancer cells cluster (arrow) are easily identifiable on a CB specimen using overnight-stored bile after centrifugation. (B) The mean number of malignant cells on a glass slide with the CB and biopsy specimens was 70 (range: 10–1110) and 110 (range: 30–280), respectively. There is no significant difference between the CB method and biopsy specimens (p = 0.17).
Figure 5Representative maspin- and p53-immunohistochemistry in the surgical, cell block (CB), and biopsy specimens. Immunohistochemistry of maspin and p53 in (A) surgical, (B) CB, and (C) biopsy specimens. While maspin staining is found in almost all malignant cells in the surgical specimen, p53 staining is sparse in the nucleus of cancer cells. (A) Although nuclear positivity of maspin is clearly observed in adenocarcinoma cells, p53 expression is weak in their cytoplasm and sparse in the nucleus of cancer cells. (B) Maspin is strongly positive in the cytoplasm of adenocarcinoma cells in the CB specimen. On the contrary, the cancer cell nuclei are sparsely stained with p53. (C) Maspin staining is positive in the cytoplasm and/or nuclei of adenocarcinoma cells in a biopsy specimen. p53 staining is positive in the nuclei of cancer cells.
Comparison of the maspin/p53-immunohistochemistry (IHC) in each specimen.
| Case | Surgical Specimen (Maspin/p53) | CB Method (Maspin/p53) | Biopsy (Maspin/p53) |
|---|---|---|---|
| 1 | 2 + /1+ | 1 + /0 | 2 + /1+ |
| 2 | 2 + /1+ | 3 + /1+ | 3 + /1+ |
| 3 | 2 + /2+ | 3 + /2+ | 2 + /3+ |
| 4 | 2 + /1+ | 2 + /0 | N.A. |
| 5 | 1 + /1+ | 1 + /0 | N.A. |
| 6 | 3 + /1+ | 3 + /2+ | N.A. |
| 7 | 3 + /2+ | 2 + /3+ | N.A. |
| 8 | 3 + /1+ | 2 + /2+ | N.A. |
IHC staining was scored from 0 to 3+ based on intensity and positive rate. N.A.: not available.
Figure 6Receiver operating characteristic curve analysis of bile volume and diagnosis of malignancy using the cell block method. The optimal cutoff was calculated as 160 mL (arrow), with a sensitivity of 43% and a specificity of 82%. The area under the curve is 0.61.